The Pharmacy Times® Gastrointestinal resource center provides news and articles centered around the FDA approved drugs in gastroenterology, as well as links to condition-specific resources, and videos and other content.
What can we help you find?
What are you going to recommend for a customer who was unable to complete a previously recommended regimen?
In a series of studies, researchers described the identification of predictive tools and a new understanding of environmental factors that trigger inflammatory bowel disease.
The goal of therapy centers on improving quality of life, maintaining remission, and preventing hospitalization and surgery.
How can this patient better tolerate polyethylene glycol (PEG)-electrolyte lavage solution?
Pre-Measured Omeprazole Suspension Kit Offers More Stability, Longer Duration Than Traditional Suspension
FIRST Omeprazole Kits offer a pre-measured option for pharmacists dispensing suspended Omeprazole.
Tofacitinib, currently used to treat rheumatoid arthritis and ulcerative colitis, has a correcting effect on defects that occur in inflammation.
Shared insight on the open dialogues that should take place between patients with opioid-induced constipation and care providers.
Key opinion leaders provide their perspectives on the goals of therapy and prophylactic management of opioid-induced constipation.
A comprehensive review of opioid-induced constipation diagnosis strategies and foundational treatment guidelines.
A panel of experts considers the disease pathology of opioid-induced constipation and the burden it has on patients.
After some lots of ranitidine were found to contain small amounts of N-nitrosodimethylamine (NDMA), Novartis's Sandoz unit has announced that they are halting distribution of ranitidine (Zantac) products until the contamination concerns are resolved.
Officials from the FDA have announced an approved package size and package type limit for over-the-counter (OTC) brand-name tablet and capsule forms of loperamide.